Company Overview and News

22
Market Update: Nifty pharma sprints ahead as Sun Pharma zooms 8%; Bajaj Finance hits new 52-week high

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday afternoon but managed to regained some lost ground with the Nifty trading lower by 11 points at 10,757 and the Sensex shed 41 points at 35,422.
500408 IOB 500325 AUROPHARMA FSL RELIANCE 532418 TCHQY 532755 511389 VIDEOIND TTNQY CADILAHC 532388 532321 500470 532540 532461 RIGD BJJQY 500570 TATAMOTORS RLNIY 500034 UBNC 532809 524804 VTUWY CDLYY 539207 TECHM 533269 BAJFINANCE TTST PNJZY TATASTEEL TATLY SINTEX ARBQY 502742 TATAELXSI TCS PNB MANPASAND WABAG ANDHRABANK TTM

16
17
Market Update: Nifty pharma outperforms, jumps 2.5% led by Sun Pharma; HPCL, BPCL shed 2%

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday morning with the Nifty trading lower by 31 points at 10,736 and the Sensex shed 87 points at 35,375.
500408 500325 AUROPHARMA FSL RELIANCE TCHQY 532755 511389 VIDEOIND TTNQY 500470 532540 RIGD AJANTPHARM 500570 TATAMOTORS RLNIY 532809 524804 532505 VTUWY 539207 TECHM 533269 532331 TTST TATASTEEL TATLY ARBQY TATAELXSI TCS UCOBANK MANPASAND WABAG TTM

2
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

2
VA Tech Wabag Limited - Investor Presentation

2018-05-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

6
Tech Mahindra, BoB, Sun Pharma results

2018-05-25 thehindubusinessline
Over 130 firms including Asahi India, BEML, BoB, Cadila Healthcare, Central Bank, Engineers India, Eris Life, Future Enterprises, Future Market, Gujarat Fluoro, Hotel Leela, Himatsingka Seide, Hind Copper, Hind Motors, IDBI Bank, India Cements, Indian Hotels, JB Chem, Jindal Saw, KV Bank, LMW, Max Financial, NBCC, NLC India, OMDC, Page Ind, PC Jeweller, PFC, Sundaram Fin, Sun Pharma, Tech Mahindra and VA Tech Wabag will announce their results on Friday.
IDBI HIMATSEIDE TCHQY 532755 CADILAHC 532321 ENGINERSIN 500850 500378 GAILF INDIACEM INDHOTEL 514043 500116 530005 VTUWY CDLYY TECHM 533269 532178 JINDALSAW GAILY 534809 PCJEWELLER WABAG

2
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

2
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

2
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

2
Company News: VA Tech Wabag

2018-05-10 thehindubusinessline
VA Tech Wabag, a leading pure-play water technology Indian multinational, has secured ₹296-crore worth order from Delhi Jal Board. The order is towards rehabilitation and upgradation of the 182 MLD waste water treatment plant at Rithala under the Yamuna Action Plan. The scope includes design, supply, construction, and commissioning, including operations and maintenance, for 11 years. The project will be financed by Japan International Cooperation Agency.
VTUWY 533269 WABAG

2
VA Tech Wabag Limited - Press Release

2018-05-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...